Reid Laurence — SEC insider filings
SEC reporting owner CIK 1492749. 9 insider filings on record with FilingPulse; latest filed 2026-09-11.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2021-09-17 to 2026-09-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 30,000 shares, $99,801 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: purchase of 10,000 shares @ $7.64 ($76,400) in Decibel Therapeutics, Inc., filed 2021-09-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Decibel Therapeutics, Inc. (DBTX) | See Remarks, Director | 4 | 1 leg · 10,000 sh · $76,400 | — | 7 |
| Metagenomi Therapeutics, Inc. (MGX) | Director | 3 | 2 legs · 20,000 sh · $23,401 | — | 2 |
| KalVista Pharmaceuticals, Inc. (KALV) | Director | 2 | — | — | 2 |
Insider filings — Reid Laurence
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-11 | 4 | Metagenomi Therapeutics, Inc. (MGX) | Purchase (P): 19,883 @ $1.17 · Purchase (P): 117 @ $1.18 | EDGAR |
| 2026-06-11 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2026-06-11 | 4 | Metagenomi Therapeutics, Inc. (MGX) | Grant/award (A): 17,400 (derivative) @ $0 | EDGAR |
| 2025-09-02 | 4 | Metagenomi, Inc. (MGX) | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2024-11-26 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-09-25 | 4 | Decibel Therapeutics, Inc. (DBTX) | Disposition to issuer (D): 220,849 · Disposition to issuer (D): 187,500 (derivative) · Disposition to issuer (D): 72,000 (derivative) · Disposition to issuer (D): 1,072,539 (derivative) | EDGAR |
| 2023-03-17 | 4 | Decibel Therapeutics, Inc. (DBTX) | Grant/award (A): 195,000 @ $0 · Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Decibel Therapeutics, Inc. (DBTX) | Grant/award (A): 187,500 (derivative) @ $0 | EDGAR |
| 2021-09-17 | 4 | Decibel Therapeutics, Inc. (DBTX) | Purchase (P): 10,000 @ $7.64 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-09-13 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1492749 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs